Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Biomedical CoTPE:7780 22 Debt-to-EBITDA is 0.21 as of Mar. 2026, which is 73% below its 10-year median of 0.77. GuruFocus rates TPE:7780 with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 1,553 Consumer Packaged Goods companies, Daiken Biomedical Co ranks better than 85% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Daiken Biomedical Co's Debt-to-EBITDA or its related term are showing as below:
TPE:7780'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.77 Max: 1.42
Current: 0.28
During the past 4 years, the highest Debt-to-EBITDA Ratio of Daiken Biomedical Co was 1.42. The lowest was 0.03. And the median was 0.77.
TPE:7780's Debt-to-EBITDA is ranked better than 85% of 1553
companies
in the Consumer Packaged Goods industry
Industry Median: 2.08
vs TPE:7780: 0.28
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Daiken Biomedical Co Debt-to-EBITDA Related Terms
Daiken Biomedical Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Daiken Biomedical Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Daiken Biomedical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Daiken Biomedical Co (TPE:7780) has a Debt-to-EBITDA of 0.21 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Daiken Biomedical Co. This is 73% below median its historical median of 0.77. Over the past decade, Daiken Biomedical Co's Debt-to-EBITDA has ranged from 0.03 to 1.42. According to the industry distribution chart, Daiken Biomedical Co ranks #233 out of 1553 companies in the Consumer Packaged Goods industry, placing it in the top 15%.
Is Daiken Biomedical Co's Debt-to-EBITDA too high?
Daiken Biomedical Co's current Debt-to-EBITDA of 0.21 is 73% below median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.42. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.08. Daiken Biomedical Co's value of 0.21 is 89.9% below this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #233 out of 1553 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Daiken Biomedical Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #233 out of 1553 companies for Debt-to-EBITDA. This places Daiken Biomedical Co in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.08. Daiken Biomedical Co's value of 0.21 is 89.9% below this benchmark. Historically, Daiken Biomedical Co's own Debt-to-EBITDA has ranged from 0.03 to 1.42 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 2.08, Daiken Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.08, based on 1,553 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current Debt-to-EBITDA of 0.21 is 89.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Daiken Biomedical Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current Debt-to-EBITDA is 0.21, which is 73% below median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current Debt-to-EBITDA of 0.21. The current Debt-to-EBITDA is 0.21, which is 73% below median its 10-year median of 0.77 and 89.9% below the Consumer Packaged Goods industry median of 2.08. Daiken Biomedical Co's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current Debt-to-EBITDA is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
22GF Score
Get the complete analysis for TPE:7780
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
